Peoples Bank OH lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 48.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 2,652 shares of the company's stock after selling 2,504 shares during the period. Peoples Bank OH's holdings in Johnson & Johnson were worth $440,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Code Waechter LLC grew its stake in shares of Johnson & Johnson by 11.3% during the first quarter. Code Waechter LLC now owns 4,546 shares of the company's stock worth $754,000 after purchasing an additional 461 shares in the last quarter. Round Rock Advisors LLC grew its stake in shares of Johnson & Johnson by 1.9% during the first quarter. Round Rock Advisors LLC now owns 9,681 shares of the company's stock worth $1,605,000 after purchasing an additional 179 shares in the last quarter. Allworth Financial LP grew its stake in shares of Johnson & Johnson by 1.8% during the first quarter. Allworth Financial LP now owns 329,321 shares of the company's stock worth $51,022,000 after purchasing an additional 5,958 shares in the last quarter. Stonebrook Private Inc. grew its stake in shares of Johnson & Johnson by 3.0% during the first quarter. Stonebrook Private Inc. now owns 23,070 shares of the company's stock worth $3,826,000 after purchasing an additional 668 shares in the last quarter. Finally, Rock Point Advisors LLC lifted its position in Johnson & Johnson by 2.1% in the first quarter. Rock Point Advisors LLC now owns 6,058 shares of the company's stock valued at $1,005,000 after acquiring an additional 125 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Trading Down 0.5%
Shares of JNJ traded down $0.82 on Friday, hitting $156.87. 7,866,488 shares of the stock traded hands, compared to its average volume of 8,066,975. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $377.44 billion, a P/E ratio of 17.45, a P/E/G ratio of 2.15 and a beta of 0.41. The stock's 50 day moving average is $153.75 and its two-hundred day moving average is $154.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's dividend payout ratio is presently 57.84%.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on JNJ shares. Raymond James Financial reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $171.00.
Check Out Our Latest Report on JNJ
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
